Johnson & Johnson Reports Strong Psoriasis Data and Q2 Earnings Growth

Johnson & Johnson (JNJ) reported positive long-term data from its ICOTYDE study on October 2, 2026, showing durable efficacy in treating psoriasis. The Phase 3 ICONIC-TOTAL study found that 70% of patients had clear or almost clear skin at Week 112, up from 57% at Week 16. Site-specific clearance rates were even more impressive, with 60% for scalp psoriasis and 89% for genital psoriasis at the two-year mark. The company also noted that safety findings remained consistent with the established profile.

Financially, Johnson & Johnson posted strong Q2 2026 results, with revenue rising 6.6% year over year to USD 25.31 billion. Adjusted EPS came in at USD 2.90, slightly above the USD 2.84 consensus estimate. The company maintained its fiscal 2026 adjusted EPS guidance of USD 11.600-11.750, with Q3 reporting scheduled for October 13, 2026.

The stock closed at USD 256.03 on the NYSE on October 2, 2026, down 1.02% from the prior close. Despite this dip, a 25-analyst consensus on September 29, 2026, gave JNJ a Moderate Buy rating and an average 12-month target of USD 274.13, which is 7.1% higher than the current price. However, potential biosimilar competition for Stelara could pose challenges for near-term pharmaceutical growth.

With a market capitalization of USD 617.0 billion and a 52-week range of USD 182.94 to USD 281.07, Johnson & Johnson remains a key player in the healthcare sector.